ArticleNeurological research and practice2026
Clinical outcomes and unmet therapeutic needs in new-onset refractory status epilepticus: evidence from a retrospective cohort.
Article in Neurological research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNew-onset refractory status epilepticus (NORSE) is a rare, life-threatening condition occurring in individuals without prior epilepsy or acute structural, toxic, or metabolic causes. Its etiology often remains cryptogenic, and inconsistent terminology hampers early recognition and treatment. This study aims to better characterize NORSE to support faster clinical diagnosis and management.
methodsWe retrospectively identified all adult patients with status epilepticus (SE) admitted to the Department of Neurology, University Hospital Marburg, Germany, between 2011 and 2023. Demographic, etiologic, treatment, and outcome data from patients fulfilling consensus criteria for NORSE were compared with those of non-NORSE patients. We additionally performed a sensitivity analysis applying strict temporal diagnostic criteria (≤ 72 h) to assess the impact of consensus-based classification on cohort definition.
resultsOf 779 patients with status epilepticus, 120 fulfilled criteria for NORSE, delineating a distinct clinical subgroup characterized by advanced age and a female predominance (67.5%, p = 0.028). Phenotypically, NORSE was strongly associated with generalized seizure semiology (70.7%, p < 0.001) and a higher burden of nonconvulsive status epilepticus (45.8%, p < 0.001), while the underlying etiology frequently remained cryptogenic (56.7%). This constellation translated into an adverse clinical trajectory, reflected by reduced rates of discharge home, increased in-hospital mortality (19.5%, p < 0.001), and greater reliance on rehabilitative care. Notably, these differences were not paralleled by alterations in metabolic indices such as HbA1c or cholesterol, underscoring the limited discriminatory value of these parameters in NORSE. Application of strict temporal criteria resulted in a smaller, more conservative NORSE cohort, while key clinical features and outcomes remained largely unchanged.
conclusionsNORSE defines a distinct and severe clinical syndrome within status epilepticus, characterized by older age, female predominance and adverse outcomes. Beyond the clinical severity of NORSE, our findings show that cohort composition is highly sensitive to the temporal operationalization of consensus criteria. Standardized application of diagnostic timing may therefore be essential for comparability across NORSE studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.